MDCG2020-10∕1修订版1 《欧盟法规(EU)2017745》下医疗器械临床研究中的安全性报告
MDCG 2020-10/1 1
EU2017/745
2022 10
2017/745 103 MDCGMDCG
Page 1 of 19
5.1
9.4
5.2.2
10.2.1
4
5
10.2.19 - 20
10.2.15 17
MDCG 2020-10/1 1
Page 2 of 19
May 2020
MDCG 2020-10 Rev 1
Safety reporting in clinical investigations
of medical devices under the Regulation (EU) 2017/745
1 ............................................................................................................................................................................................................................................................................................................ 3
1.1 EUDAMED ...................................................................................................................................................................................................................................................................3
2 ............................................................................................................................................................................................................................................................................................................ 4
2.1 ............................................................................................................................................................................................................................................................................................................4
2.2 ..................................................................................................................................................................................................................................................................4
3 ............................................................................................................................................................................................................................................................................................................ 5
3.1 ........................................................................................................................................................................................................................................................................................5
3.2 AE ............................................................................................................................................................................................................................................................................ 5
3.3 SAE .................................................................................................................................................................................................................................................................. 5
3.4 ............................................................................................................................................................................................................................................................................................5
4 ..................................................................................................................................................................................................................................................................................................... 6
4.1 EUDAMED .............................................................................................................................................................................................................................................................................6
4.2 NCAS ......................................................................................................................................................................................................................................................................6
4.3 ........................................................................................................................................................................................................................................................................................................6
5 ............................................................................................................................................................................................................................................................................................... 7
5.1 74.1 PMCF ............................................................................................................................................................................................................7
5.2 .............................................................................................................................................................................................................................................................7
5.3 ..........................................................................................................................................................................................................................................7
5.4 PMCF ......................................................................................................................................................................................................................................8
6 ........................................................................................................................................................................................................................................................................................ 8
7 .................................................................................................................................................................................................................................................................................................... 8
8 ............................................................................................................................................................................................................................................................................................... 8
8.1 NCAS .............................................................................................................................................................................................................................................................................................8
8.2 ................................................................................................................................................................................................................................................................................................9
9 ............................................................................................................................................................................................................................................................................................ 9
10 .................................................................................................................................................................................................................................................................................................. 11
10.1 ................................................................................................................................................................................................................................................................................11
10.2 ........................................................................................................................................................................................................................................................................13
11 .................................................................................................................................................................................................................................................................................................. 16
12 ...................................................................................................................................................................................................................................................... 16
Page 3 of 19
摘要：
展开>>
收起<<
MDCG2020101OrH10kvlEU20177450NSuVhhN4xzvNvQhbTJ2022t10ggeNu1kv2017745Sl103gazvSuVhhSOMDCGS0MDCGu1bgbTXVvNhbu1kvYTXOvNTNhbNN0eNvkm2YTXOeNNNSfkm2YTXOvezW0geNNhvNOUpWGNQwglgRSgkm2TvlbYkvlOQQwggRv0Page1of19evxNR5194onon522102145hhQS10219201021517eNIMDCG2020101OrH1vSfQsNbTJLvfQsNXkQbTJhvffePage2of19May20...
声明：如果您的权利被侵害，请联系我们的进行举报。
相关推荐
-
YY 1042-2023 牙科学 聚合物基修复材料VIP免费
2024-04-11 145 -
YY∕T 1465.1-2016 医疗器械免疫原性评价方法 第1部分：体外T淋巴细胞转化试验VIP免费
2024-04-15 207 -
YY∕T 1465.2-2016 医疗器械免疫原性评价方法 第2部分：血清免疫球蛋白和补体成分测定（ELISA法）VIP免费
2024-04-15 97 -
YY∕T 1465.3-2016 医疗器械免疫原性评价方法 第3部分：空斑形成细胞测定琼脂固相法VIP免费
2024-04-15 152 -
YY∕T 1789.2-2021 体外诊断检验系统性能评价方法 第2部分：正确度
2024-10-07 293 -
YY∕T 1789.1-2021 体外诊断检验系统性能评价方法 第1部分：精密度
2024-10-07 538 -
YY∕T 1789.6-2023体外诊断检验系统 性能评价方法 第6部分：定性试剂的精密度、诊断灵敏
2024-10-07 200 -
YY∕T 1789.4-2022 体外诊断检验系统 性能评价方法 第4部分：线性区间与可报告区间
2024-10-07 295 -
YY∕T 1789.3-2022 体外诊断检验系统 性能评价方法 第3部分：检出限与定量限
2024-10-07 230 -
YY∕T 1789.5-2023 体外诊断检验系统 性能评价方法 第5部分：分析特异性
2024-10-07 245
作者：一如既往
分类：法规规范
价格：100质量币
属性：19 页
大小：3.03MB
格式：PDF
时间：2026-03-17
